Trial Profile
A Multi-center, Randomized, Open-label, Non Inferiority Trial to Evaluate the Efficacy and Safety of a Single, Oral Dose of Zoliflodacin Compared to a Combination of a Single Intramuscular Dose of Ceftriaxone and a Single Oral Dose of Azithromycin in the Treatment of Patients With Uncomplicated Gonorrhoea
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Zoliflodacin (Primary) ; Azithromycin; Ceftriaxone
- Indications Gonococcal urethritis; Gonorrhoea
- Focus Registrational; Therapeutic Use
- 01 Nov 2023 According to an Innoviva media release, Primary endpoint (Efficacy of a single dose of zoliflodacin will be assessed compared to a combination of a single dose of ceftriaxone and azithromycin.) has been met.
- 01 Nov 2023 According to an Innoviva media release, company announced positive topline data from this zoliflodacin data for treatment of gonorrhea in November 2023.
- 02 Aug 2023 According to an Innoviva media release, topline results are expected in late 2023.